2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 702

Is Skin Disease More Important to Patients or Physicians in the Assessment of Disease Activity in Psoriatic Arthritis?
Abstract Number: 701

Is Skin Disease More Important to Women or Men in the Assessment of Disease Activity in Psoriatic Arthritis?
Abstract Number: 2816

Is the Gender Difference in As Linked to IL-23?
Abstract Number: 1881

Is the Presence of Esophageal Dilation a Poor Prognostic Factor in Dilated Interstitial Lung Disease Associated with Systemic Sclerosis?
Abstract Number: 413

Is There a Difference in the Presentation of Diffuse and Limited Subtype of Juvenile Systemic Sclerosis in Childhood? Results from the Juvenile Scleroderma Inception Cohort Www.Juvenile-Scleroderma.Com
Abstract Number: 1793

Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus
Abstract Number: 1401

Is There Any Difference Between Autoimmune or Hemato-Oncology Etiology of Macrophage Activation Syndrome?
Abstract Number: 1736

Is There Evidence to Support Replacing Conventional AP Pelvis Radiographs with Dedicated Sacroiliac Joint Views for the Diagnosis of Sacroiliitis?
Abstract Number: 2295

Is There Peripheral Large Nerve Involvement in Fibromyalgia? a Systematic EMG / Nerve Conduction Study Evaluation of 55 Consecutive FM Patients
Abstract Number: 3184

Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
Abstract Number: 1523

Ischemia Modified Albumin Levels in Rheumatoid Arthritis
Abstract Number: 632

Isolated Atrioventricular Block of Unknown Origin in the Adult and Autoimmunity: Diagnostic and Therapeutic Considerations Exemplified By Three Anti-Ro/SSA-Associated Cases
Abstract Number: 1928

Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis
Abstract Number: 703

Isotretinoin-Induced Spondilartropathy-Related Symptoms: A Prospective Study
Abstract Number: 269

Items of Yamaguchi Criteria Might be Associated with Disease Severity and Prognosis in Adult-Onset Still’s Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].